Core Viewpoint - Yunnan Baiyao demonstrated resilient growth in the first half of 2025, overcoming multiple external challenges while optimizing its business structure [1] Financial Performance - The company achieved revenue of 21.26 billion yuan, representing a year-on-year increase of 3.9% [1] - The net profit attributable to shareholders reached 3.63 billion yuan, with a year-on-year growth of 13.9% [1] Business Structure Optimization - The industrial sales revenue accounted for 40.0% of total revenue, an increase of 2.6 percentage points year-on-year [1] - The gross margin improved to 30.9%, reflecting a year-on-year increase of 1.6 percentage points [1] Growth Drivers - The pharmaceutical and health product segments are driving growth through a dual-engine strategy [1] - The company is enhancing innovation and systematically advancing its pipeline layout [1] Valuation - Based on the average price-to-earnings ratio of comparable companies, a valuation of 23 times PE for 2025 is suggested, corresponding to a target price of 65.78 yuan, maintaining a "buy" rating [1]